Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4 Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason – SPDR Select Sector Fund – Health Care (ARCA:XLV), iShares Biotechnology ETF (NASDAQ:IBB) – Stocks to Watch
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason – SPDR Select Sector Fund – Health Care (ARCA:XLV), iShares Biotechnology ETF (NASDAQ:IBB)
The Health Care Select Sector SPDR FundXLV, heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies reporting annual earnings.
Shares of Health Care Select Sector SPDR Fund opened at $129.26 on Monday, with a twelve-month low of $118.75 and a twelve-month high of $143.42. YTD shares lost 6.54%.
Top holding companies Merck & Co IncMRK, AbbVie IncABBV, Eli Lilly And CoLLY, Thermo Fisher Scientific IncTMO, Abbott LaboratoriesABT, and Bristol Meyers Squibb & CoBMY reported their Q4 earnings during the month.
Over the month, Lilly stock lost 5.5%, Thermo Fisher fell 2.45%, Abbott lost 6.54%, Bristol Myers slipped 7.2%, while Merck shares gained 6.28%, and AbbVie jumped 7.2%.
Over one month, iShares Biotechnology ETFIBB shares have fallen 4.3%, with stock opening at $130.27.
Today, Aclaris Therapeutics IncACRS was retreating nearly 40% after zunsemetinib did not meet its primary and secondary efficacy endpoints.
Adaptimmune Therapeutics IncADAP and TCR2 Therapeutics IncTCRRagreed to merge.
TCR2 was rising over 25% in value, while Adaptimmune Therapeutics was down more than 20%.
BridgeBio Pharma IncBBIO shares are gaining over 50% after positive data from the PROPEL2 Phase 2 trial of infigratinib in the form of dwarfism.
Price Action: XLV shares closed down 1.60% at $127.04, and IBB closed down 1.59% at $127.25 on Tuesday.
